Axa Rosenberg's model involves thousands of multivariate regression calculations, but it all boils down to the same thing that old-fashioned value investors are looking for: an estimate of fairvalue, which is then compared with current stock prices.
Again, at the current trading levels for Monsanto we are getting the Seed and Genomics business at fairvalue and the rest of Monsanto for almost nothing.